ClinicalTrials.gg
CompletedNCT03190330Updated May 25, 2025Results posted

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

A Phase 4 interventional study of Ibrutinib 420 mg and Ibrutinib 560 mg in Leukemia, Lymphocytic, Chronic, B-Cell and Lymphoma, Mantle-Cell, sponsored by Johnson & Johnson Private Limited. Completed at 10 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Johnson & Johnson Private Limited (part of Johnson & Johnson) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
29th of 83
75 · median 44
Started
2019
with 6 others
Phase 4
Only one
of the 83
Registered
52nd of 83
by date

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 29th largest by enrollment, is one of 7 that started in 2019, is the only one in phase 4, and was the 52nd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the post-marketing safety of ImbruvicaTM (ibrutinib capsule 140 milligram [mg]) under actual conditions of use, and to understand the incidence of adverse events (AEs) (serious and non-serious AEs).

03

Conditions studied

  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Mantle-Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) participants being newly initiated on Imbruvica treatment (ibrutinib capsule 140 milligram [mg]) based on independent clinical judgment of treating physicians as per locally approved prescribing information
  • Must give a written indicating that they understand the purpose and are willing to participate in the study and allowing data collection and source data verification in accordance with regulatory requirements

Exclusion criteria

Exclusion Criteria:

  • Participants who are not eligible to receive Imbruvica as per the locally approved prescribing information
  • Participants participating or planning to participate in any interventional drug trial during the course of this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Ibrutinib

    Participants will receive ibrutinib 420 milligram (mg) (three 140 mg capsules) as a single daily dose for chronic lymphocytic leukemia (CLL) and 560 mg (four 140 mg capsules) as a single daily dose for mantle cell lymphoma (MCL) for up to 12 months or till disease progression, whichever is earlier.

    Drug: Ibrutinib 420 mg · Drug: Ibrutinib 560 mg

Interventions

  • Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.

    Also known as: Imbruvica

  • Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.

    Also known as: Imbruvica

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Any AE occurred at or after the initial administration of study drug up to maximum of 30 days after last dose was considered as treatment emergent.

    Time frame: Day 1 up to 30 days after last dose of study drug (up to 13 months)

  2. Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was an AE which resulted in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurred at or after the initial administration of study drug up to maximum of 30 days after last dose was considered as treatment emergent.

    Time frame: Day 1 up to 30 days after last dose of study drug (up to 13 months)

07

Results

Posted May 21, 2024

Participant flow

Participant flow — Overall Study
MilestoneIbrutinib
Started75
Participants with cll67
Participants with mcl8
Completed55
Not completed20
Withdrew: Adverse event2
Withdrew: Death10
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject6
Withdrew: Progressive disease1

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Any AE occurred at or after the initial administration of study drug up to maximum of 30 days after last dose was considered as treatment emergent.

Time frame:
Day 1 up to 30 days after last dose of study drug (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsIbrutinib
Number of Participants With Treatment Emergent Adverse Events (TEAEs)62
PrimaryNumber of Participants With Treatment Emergent Serious Adverse Events (TESAEs)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was an AE which resulted in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurred at or after the initial administration of study drug up to maximum of 30 days after last dose was considered as treatment emergent.

Time frame:
Day 1 up to 30 days after last dose of study drug (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsIbrutinib
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)23

Adverse events

Collected over Day 1 up to 30 days after last dose of study drug (up to 13 months). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib10/75 (13.3%)23/75 (30.7%)55/75 (73.3%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventIbrutinib
PyrexiaGeneral disorders4/75
Covid-19Infections and infestations3/75
Cardio-Respiratory ArrestCardiac disorders2/75
Febrile NeutropeniaBlood and lymphatic system disorders1/75
PancytopeniaBlood and lymphatic system disorders1/75
Acute Coronary SyndromeCardiac disorders1/75
Abdominal PainGastrointestinal disorders1/75
DeathGeneral disorders1/75
Disease ProgressionGeneral disorders1/75
Non-Cardiac Chest PainGeneral disorders1/75
Most frequent other events
Showing 10 of 40
Most frequent other events
EventIbrutinib
AnaemiaBlood and lymphatic system disorders12/75
VomitingGastrointestinal disorders8/75
PyrexiaGeneral disorders8/75
CoughRespiratory, thoracic and mediastinal disorders8/75
FatigueGeneral disorders7/75
HeadacheNervous system disorders7/75
DiarrhoeaGastrointestinal disorders6/75
Decreased AppetiteMetabolism and nutrition disorders6/75
FuruncleInfections and infestations5/75
ArthralgiaMusculoskeletal and connective tissue disorders5/75

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ibrutinib
Mean61.9 ± 11.81
Sex: Female, Male
Sex: Female, Male(Participants)Ibrutinib
Female23
Male52
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ibrutinib
Hispanic or Latino0
Not Hispanic or Latino0
Unknown or Not Reported75
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ibrutinib
American Indian or Alaska Native0
Asian75
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Ibrutinib
India75
08

Study locations

10 sites
  • Avron Hospitals Pvt. Ltd
    Ahmedabad, 380013, India
  • Post Graduate Institute of Medical Education And Research PGIMER
    Chandigarh, 160012, India
  • Basavatarakam Indo-American Hospital
    Hyderabad, 500034, India
  • Bhagwan Mahaveer Cancer Hospital & Research Centre
    Jaipur, 302017, India
  • Cytecare Hospitals Pvt. Ltd
    Karnataka, 560064, India
  • Apollo Multispeciality Hospital Ltd
    Kolkata, 700019, India
  • Tata Medical Center
    Kolkata, 700156, India
  • Jawaharlal Institute of Postgraduate Medical Education and Research
    Pondicherry, 605008, India
  • Deenanath Mangeshkar Hospital and Research Centre
    Pune, 411004, India
  • Noble Hospital Pvt Ltd
    Pune, 411013, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in May 2023, 46 months.

Results were first posted in May 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2017
First posted
Jun 16, 2017
StartActual
Jun 26, 2019
Primary completionActual
May 3, 2023
CompletionActual
May 3, 2023
Results first posted
May 21, 2024
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03190330
Responsible party
Sponsor
First posted
Jun 16, 2017
Start date
Jun 26, 2019
Primary completion
May 3, 2023
Completion
May 3, 2023
Results posted
May 21, 2024
Last update
May 25, 2025

Study contacts

Johnson & Johnson Private Limited Clinical Trial
study director · Johnson & Johnson Private Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion